2022 · Benjamin — A potential clinical application of hydrogen-rich saline in patients with traumatic brain injury.

Traumatic brain injury triggers a cascade of secondary damage mechanisms — neuroinflammation, oxidative stress, excitotoxicity, and mitochondrial dysfunction — that unfold in the hours and days after the primary injury. This secondary injury phase is the therapeutic window where interventions could potentially limit damage. Hydrogen-rich saline (administered intravenously) is proposed as an agent that could reach the brain rapidly, neutralise excess reactive oxygen species, and reduce inflammatory signalling without the side effects of many conventional agents. The paper appears in a pediatric surgery journal, suggesting the focus may be on pediatric TBI patients. However, the abstract is not publicly available in the source used, so specific trial design, patient numbers, outcomes, and statistical results cannot be verified from available data. The classification as ev=2 (human study) indicates the paper involves human subjects, making it more than a purely preclinical review.

This study addresses a high-priority clinical unmet need — effective neuroprotective treatments for TBI remain limited. Hydrogen-rich saline is a biologically plausible candidate given its known antioxidant and anti-inflammatory properties. Critical limitation: no abstract was available in the source data, making independent assessment of methodology, sample size, control design, endpoints, and outcomes impossible. Given publication in the Journal of Pediatric Surgery (2022), readers should consult the original paper (DOI: 10.1016/j.jpedsurg.2022.06.007) for full evaluation before drawing clinical conclusions.